DavidTTeacheyMD
Pediatric Hematology & Oncology • Philadelphia, PAProfessor at Children's Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine
Dr. Teachey is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3401 Civic Center Blvd
# Children
Philadelphia, PA 19104Phone+1 215-590-3535Fax+1 215-590-3992
Summary
- Dr. David Teachey is a specialist in Pediatric Hematology & Oncology based in Philadelphia, PA. He completed his residency at Children's National Medical Center and further enhanced his skills at Children's Hospital of Philadelphia. With his extensive experience in lymphoblastic leukemia, lymphoma, and autoimmune diseases, he currently serves as a Professor at the Perelman School of Medicine and as an Attending Physician at the Children's Hospital of Philadelphia.
Education & Training
Children's Hospital of Philadelphia2005
Children's National HospitalResidency, Pediatrics, 1999 - 2002
Eastern Virginia Medical SchoolClass of 1999
Certifications & Licensure
FL State Medical License 2021 - Present
PA State Medical License 2002 - 2024
VA State Medical License 2021 - 2024
NY State Medical License 2021 - 2023
NC State Medical License 2020 - 2022
DC State Medical License 2001 - 2004- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Sirolimus for Autoimmune Disease of Blood Cells Start of enrollment: 2006 Dec 01
- Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH) Start of enrollment: 2013 Dec 01
- Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma Start of enrollment: 2014 Oct 04
Publications & Presentations
PubMed
- 1 citationsA multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia.Jason Xu, Changya Chen, Jonathan H Sussman, Satoshi Yoshimura, Tiffaney Vincent
Nature Cancer. 2024-11-25 - 1 citationsDaratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study.Teena Bhatla, Laura E Hogan, David T Teachey, Francisco Bautista, John Moppett
Blood. 2024-11-21 - Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks.Caroline Diorio, David T Teachey, Stephan A Grupp
Nature Reviews. Clinical Oncology. 2024-11-15
Journal Articles
- Targeting EIF4E Signaling with Ribavirin in Infant Acute Lymphoblastic LeukemiaNyla A Heerema, James W Davenport, Carolyn A Felix, Andrew J Carroll, ZoAnn E Dreyer, Alix E Seif, David T Teachey, Joanne M Hilden, Sarah K Tasian, Cheryl L Willman, ..., Nature
Authored Content
- Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-acute Lymphoblastic Leukemia: Results from the Randomized Children’s Oncology Group Study AALL1731December 2024
Press Mentions
New Research from Children's Hospital of Philadelphia to Transform Standard of Care Across the Globe for Newly Diagnosed Children with B-cell Acute Lymphoblastic LeukemiaDecember 7th, 2024
Gene Signature for High-Risk Form of Acute Lymphoblastic Leukemia Identified by CHOP ScientistsNovember 26th, 2024
Multiomic Signatures Identified for Rapid Detection and Treatment of High-Risk T-ALLNovember 24th, 2024- Join now to see all
Grant Support
- Targeting The Mtor Signaling Pathway In Autoimmune Lymphoproliferative SyndromeNational Institute Of Allergy And Infectious Diseases2011
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
